All NIH Funding Opportunities and Notices

Notices

- **Notice of Correction to Announcement Type for PAR-18-387 "Education and Health: New Frontiers (R01) Clinical Trial Optional"**
  (NOT-OD-18-190)
  Office of the Director, NIH

- **Request for Information (RFI): Input on Report from Council of Councils on Assessing the Safety of Relocating At-Risk Chimpanzees**
  (NOT-OD-18-191)
  Office of the Director, NIH

- **Early Registration Ends June 29 for Fall 2018 NIH Regional Seminar in San Francisco, CA**
  (NOT-OD-18-192)
  Office of the Director, NIH

- **Notice to Extend the Expiration Date for PAR-15-356 "Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01)"**
  (NOT-AG-18-014)
  National Institute on Aging

- **Notice to Extend the Expiration Date for PAR-15-358 "Capturing Complexity in the Molecular and Cellular Mechanisms Involved in the Etiology of Alzheimer's Disease (R01)"**
  (NOT-AG-18-018)
  National Institute on Aging

- **NIAID Policy for T32 and T35 Competing Renewal Application Submissions**
  (NOT-AI-18-040)
  National Institute of Allergy and Infectious Diseases

- **Notice of Availability of Administrative Supplements to Support Tool and Resource Development to Address Racial and Ethnic Disparities in Multiple Myeloma**
  (NOT-CA-18-077)
  National Cancer Institute

- **Notice of Availability of Administrative Supplements to NIBIB Grants: Technology Dissemination**
  (NOT-EB-18-019)
  National Institute of Biomedical Imaging and Bioengineering

- **Notice of Availability of Administrative Supplements to NIBIB Grants: Personalized Imaging Technologies**
  (NOT-EB-18-020)
  National Institute of Biomedical Imaging and Bioengineering

- **Notice of Availability of Administrative Supplements to NIBIB Grants: Machine Learning and Deep Learning Solutions**
  (NOT-EB-18-021)
  National Institute of Biomedical Imaging and Bioengineering

- **Notice of Change to Application Due Date in RFA-RM-18-006 "Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 - Clinical Trial Not Allowed)"**
  (NOT-GM-18-035)
  National Institute of General Medical Sciences
• **Phase-out and Termination of NIGMS Participation in the NIH MERIT (R37) Program**
  (NOT-GM-18-036)
  National Institute of General Medical Sciences

• **Notice of Frequently Asked Questions for RFA-HL-19-009 "Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (UM1 Clinical Trial Not Allowed)"**
  (NOT-HL-18-636)
  National Heart, Lung, and Blood Institute

• **Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Trials Network on Pain Research - Data Coordinating Center (U24 Clinical Trial Not Allowed)**
  (NOT-NS-18-057)
  National Institute of Neurological Disorders and Stroke

• **Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Trials Network on Pain Research Clinical Coordinating Center (U24 Clinical Trials not Allowed)**
  (NOT-NS-18-058)
  National Institute of Neurological Disorders and Stroke

• **Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Centers for the Clinical Trials Network on Pain Research (CTNPR) (U24 Clinical Trial Not Allowed)**
  (NOT-NS-18-069)
  National Institute of Neurological Disorders and Stroke

• **Notice of New Budget Limitation for PAR-16-331 Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)**
  (NOT-NS-18-071)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• **Notice of New Budget Limitation for PAR-18-657 Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional).**
  (NOT-NS-18-072)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• **Notice to update Application Types Allowed for PAR-18-464: Clinical and Translational Science Award (U54 Clinical Trial Optional)**
  (NOT-TR-18-028)
  National Center for Advancing Translational Sciences
Requests for Applications

- **Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)**
  (RFA-AI-18-006)
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  Application Receipt Date(s): November 30, 2018, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on this date.

- **Immune Mechanisms at the Maternal-Fetal Interface (R01 Clinical Trial Optional)**
  (RFA-AI-18-023)
  National Institute of Allergy and Infectious Diseases
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  Application Receipt Date(s): October 4, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)**
  (RFA-CA-18-015)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this FOA. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)**
  (RFA-CA-18-016)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UG1 Clinical Trial Required)**
  (RFA-CA-18-017)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)**
  (RFA-DK-18-009)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 14, 2019, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

- **Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)**
  (RFA-HD-19-015)
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  Application Receipt Date(s): November 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Large Animal Testing Centers for Evaluation of Somatic Cell Genome Editing Tools (U42 - Clinical Trial Not Allowed) (RFA-RM-18-014)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): August 24, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Program Announcements

Minor Use Minor Species Development of Drugs (R01) (PAR-18-827)
Food and Drug Administration
Application Receipt Date(s): August 27, 2018; January 18, 2019; August 16, 2019; January 17, 2020; August 14, 2020; January 15, 2021 by 11:59 PM Eastern Time Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) (PAR-18-828)
National Center for Complementary and Integrative Health
Office of Dietary Supplements
Application Receipt Date(s): New Applications: August 31, 2018; February 7, 2019; and October 8, 2019 by 5:00 PM local time of applicant organization. Resubmission Applications: September 7, 2018; February 21, 2019; and October 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) (PAR-18-829)
National Center for Complementary and Integrative Health
Office of Dietary Supplements
Application Receipt Date(s): New Applications: August 31, 2018; February 7, 2019; and October 8, 2019 by 5:00 PM local time of applicant organization. Resubmission Applications: September 7, 2018; February 21, 2019; and October 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed) (PAR-18-830)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Cancer Institute
National Eye Institute
Application Receipt Date(s): November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed) (PAR-18-831)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• **AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)**
  (PAR-18-832)
  National Institute of Mental Health
  Application Receipt Date(s): September 11, 2018, September 11, 2019, September 11, 2020, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• **Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)**
  (PAR-18-833)
  National Institute of Mental Health
  Application Receipt Date(s): September 11, 2018, September 11, 2019, September 11, 2020, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

You have received this information as a result of being subscribed to the UTHSCSA Office of Sponsored Programs fundinginfo2 ListServ. To remove yourself from this list, visit the Subscriber’s Corner in the List Archives [http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2](http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2), and follow the onscreen instructions to log in and manage your list subscriptions.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *